{"id":5989,"date":"2025-12-10T07:46:07","date_gmt":"2025-12-10T15:46:07","guid":{"rendered":"https:\/\/www.iths.org\/participate\/?p=5989"},"modified":"2025-12-10T07:46:07","modified_gmt":"2025-12-10T15:46:07","slug":"true-hs1-ruxolitinib-cream-study","status":"publish","type":"post","link":"https:\/\/www.iths.org\/participate\/true-hs1-ruxolitinib-cream-study\/","title":{"rendered":"TRuE-HS1 Ruxolitinib Cream Study"},"content":{"rendered":"
<\/div>\n

This study aims to evaluate the safety and effects of a study cream called ruxolitinib compared with a vehicle cream in individuals with Hidradenitis Suppurativa. The vehicle cream, which does not contain the active drug, will be used to help determine whether the study cream provides greater benefits. Ruxolitinib is an investigational cream, which means it has not been approved by the Food and Drug Administration (FDA) for people with HS, but it has been approved for use in people with other skin conditions like atopic dermatitis. Participation will start with a 28-day screening period, followed by 16 weeks of applying the study cream or placebo cream twice a day (this is a double-blind period), with 6 visits over that time period; followed by 36 weeks, with 9 visits over that time period, applying the study cream twice a day (this is an open-label period). There will be a follow up visit 30 days after the last application of study cream. During these visits participants may have a physical exam, blood draw, have skin examined for lesions and those present counted, and asked to fill out a diary, questionnaires and surveys. Participants will also be asked to complete a daily questionnaire, as well as an application diary. Participants could receive compensation for taking part in the study and reimbursement for travel.<\/p>\n

Participant Eligibility<\/h3>\n

\u2022 Be at least 12 years old
\n\u2022 Have HS for at least 6 months
\n\u2022 Agree to not use other products or medications for HS<\/p>\n

Contact<\/h3>\n

Camila Marquez
\n(206) 543-5312<\/p>\n

<\/p>\n

Additional Study Details<\/h3>\n

Full Study Title<\/strong>
\nA Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa: Topical Ruxolitinib Evaluation in Hidradenitis Suppurativa (TRuE-HS1)
\n<\/span><\/p>\n

Study ID:<\/strong> TRuE-HS1 Ruxolitinib Cream Study<\/div>\n
ClinicalTrials.gov Link:<\/strong> NCT06958211<\/a><\/div>\n
<\/div>\n
Start Date:<\/strong> 12\/03\/2025<\/div>\n
End Date:<\/strong> 12\/31\/2027<\/div>\n
<\/div>\n

Investigator(s)<\/strong>
\nDr. Vivian Shi, Dr. Song Park
\n<\/span>
\nAccepts Healthy Volunteers?<\/strong>
\nNo<\/span><\/p>\n

Study Site(s)<\/strong><\/p>\n

\n

University of Washington, Roosevelt Clinic<\/h4>\n

4225 Roosevelt Way NE
\nSeattle, Washington 98105<\/p>\n<\/div>\n

\n

<\/h4>\n<\/div>\n
<\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

This study aims to evaluate the safety and effects of a study cream called ruxolitinib compared with a vehicle cream in individuals with Hidradenitis Suppurativa. The vehicle cream, which does not contain the active drug, will be used to help determine whether the study cream…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21],"tags":[1694,1203,65,1692,1693,1087],"class_list":["post-5989","post","type-post","status-publish","format-standard","hentry","category-skin-hair-and-nails","tag-acne-inversa","tag-adult","tag-children","tag-dermatology","tag-hidradenitis-suppurativa","tag-pediatrics"],"_links":{"self":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/5989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/comments?post=5989"}],"version-history":[{"count":2,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/5989\/revisions"}],"predecessor-version":[{"id":5991,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/5989\/revisions\/5991"}],"wp:attachment":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/media?parent=5989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/categories?post=5989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/tags?post=5989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}